EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Model-informed dose optimization for prophylactic piperacillin-tazobactam in perioperative pediatric critically ill patients

Wen Rui Tan iD, Kei Irie, Carter McIntire, Julie Luna Torres, Rhonda Jones, Abigayle Gibson, Tomoyuki Mizuno, Sonya Tang Girdwood iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01227-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Wen Rui Tan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and System Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Piperacillin, Tazobactam Drug Combination, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, HHS | NIH | National Institute of General Medical Sciences (NIGMS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Piperacillin/tazobactam (PTZ) is frequently prescribed during the perioperative period as prophylaxis in critically ill patients. Current international guidelines recommend that the pediatric intraoperative dosing regimen for PTZ be 90–112.5 mg/kg (80–100 mg/kg as piperacillin [PIP]) administered every 2 hours (Q2H). Concerns have been raised not only about the risk of nephrotoxicity due to elevated PIP exposure but also regarding the practicality of adhering to a 2-h dosing interval in clinical settings. To address these concerns, we employed population pharmacokinetic (PK) modeling and simulation approaches to optimize PTZ dosing regimens in pediatric intraoperative patients. PIP plasma concentration data were obtained from 34 patients using an opportunistic sampling strategy. A two-compartment model was found to adequately describe the PK data. Creatinine clearance was identified as a significant covariate on clearance. The inclusion of inter-occasion variability significantly improved model fit. Simulations across body weights of 10–70 kg and creatinine clearance of 20–130 mL/min/1.73 m 2 demonstrated that 6–15 mg/kg Q2H, or a 10 mg/kg loading dose followed by 1.0–2.75 mg/kg/h continuous infusion would achieve free PIP concentrations being above the minimum inhibitory concentration (MIC) for 100% of the dosing interval (100% f T >1× MIC). For achieving 100% f T >4× MIC, 25–55 mg/kg Q2H or a 20 mg/kg loading dose followed by 3.25–9.25 mg/kg/h continuous infusion was derived. The model-informed simulations indicated that both lower Q2H doses and continuous infusion methods are clinically viable options and potentially resolve current clinical challenges during intraoperative dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Piperacillin, Tazobactam Drug CombinationAnti-Bacterial AgentsHumansCritical IllnessMaleFemaleChildChild, PreschoolInfantPiperacillinAdolescentCreatinineMicrobial Sensitivity TestsAntibiotic Prophylaxis

Stichwörter der Autor:innen

beta-lactammodeling and simulationpopulation pharmacokinetic

Substanzen

Piperacillin, Tazobactam Drug CombinationAnti-Bacterial AgentsPiperacillinCreatinine

Autor:innen und Institutionen

  • Department of Pharmacology and System Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Hospital Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

ORCID-Profile: Wen Rui Tan, Sonya Tang Girdwood

Förderung

  • NIGMS NIH HHS
  • HHS | NIH | National Institute of General Medical Sciences (NIGMS)

Zitieren

APA

Tan, W. R., Irie, K., McIntire, C., Torres, J. L., Jones, R., Gibson, A., Mizuno, T., & Tang Girdwood, S. (2025). Model-informed dose optimization for prophylactic piperacillin-tazobactam in perioperative pediatric critically ill patients. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01227-24

Vancouver

Tan WR, Irie K, McIntire C, Torres JL, Jones R, Gibson A, et al. Model-informed dose optimization for prophylactic piperacillin-tazobactam in perioperative pediatric critically ill patients. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01227-24

BibTeX
@article{Tan2025,
  author = {Tan, Wen Rui and Irie, Kei and McIntire, Carter and Torres, Julie Luna and Jones, Rhonda and Gibson, Abigayle and Mizuno, Tomoyuki and Tang Girdwood, Sonya},
  title = {Model-informed dose optimization for prophylactic piperacillin-tazobactam in perioperative pediatric critically ill patients},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01227-24}
}
Kostenlos starten →